Evidence for activation of the tissue kallikrein-kinin system in nociceptive transmission and inflammatory responses of mice using a specific enzyme inhibitor

Detalhes bibliográficos
Autor(a) principal: Emim, José AD
Data de Publicação: 2000
Outros Autores: Souccar, Caden [UNIFESP], Castro, Maria SD, Godinho, Rosely Oliveira [UNIFESP], Cezari, Maria HS, Juliano, Luiz [UNIFESP], Lapa, Antonio José [UNIFESP]
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da UNIFESP
Texto Completo: http://dx.doi.org/10.1038/sj.bjp.0703362
http://repositorio.unifesp.br/handle/11600/26331
Resumo: 1 the pharmacological activity of phenylacetyl-Phe-Ser-Arg-N-(2,4-dinitrophenyl)-ethylenediamine (TKI), a tissue kallikrein specific inhibitor, was assessed using models of nociception and inflammation in mice.2 Injection of TKI (13.6-136 mu mol kg(-1), i.p. or 41-410 mu mol kg(-1), s.c.) produced a dose-related inhibition of the acetic acid-induced writhes (by 37 to 85% or 34 to 80%, respectively). the antinociceptive activity of TKI (41 mu mol kg(-1), i.p.) was maximal after 30 min injection and lasted for 120 min. the effect was unaltered by pretreatment with naloxone (8.2 mu mol kg(-1), s.c.) or bilateral adrenalectomy.3 TRI (41 and 136 mu mol kg(-1), i.p.) produced a dose-related decrease of the late phase of formalin-induced nociception by 79 and 98%, respectively. At 136 mu mol kg(-1), i.p., TKI also shortened the duration of paw licking in the early phase by 69%. TKI (41 and 136 mu mol kg(-1), i.p.) also reduced the capsaicin-induced nociceptive response (by 51 to 79%).4 TKI (41 pmol kg(-1), i.p. or 410 mu mol kg(-1), s.c.) reduced the oedematogenic response, from the second to the fifth hour after carrageenin injection by 36 to 30% or by 47 to 39%, respectively.5 Pretreatment with TKI (41 mu mol kg(-1), i.p.) reduced the capsaicin-induced neurogenic inflammation in the mouse ear by 54%.6 It is concluded that TKI presents antinociceptive and antiinflammatory activities mediated by inhibition of kinin formation by tissue kallikrein in mice. the results also indicate that the tissue kallikrein-dependent pathway contributes to kinin generation in nociceptive and inflammatory processes in mice.
id UFSP_122003536123217729ed8e7eb1b61ff3
oai_identifier_str oai:repositorio.unifesp.br/:11600/26331
network_acronym_str UFSP
network_name_str Repositório Institucional da UNIFESP
repository_id_str 3465
spelling Evidence for activation of the tissue kallikrein-kinin system in nociceptive transmission and inflammatory responses of mice using a specific enzyme inhibitortissue kallikrein inhibitorkininsnociceptioninflammation1 the pharmacological activity of phenylacetyl-Phe-Ser-Arg-N-(2,4-dinitrophenyl)-ethylenediamine (TKI), a tissue kallikrein specific inhibitor, was assessed using models of nociception and inflammation in mice.2 Injection of TKI (13.6-136 mu mol kg(-1), i.p. or 41-410 mu mol kg(-1), s.c.) produced a dose-related inhibition of the acetic acid-induced writhes (by 37 to 85% or 34 to 80%, respectively). the antinociceptive activity of TKI (41 mu mol kg(-1), i.p.) was maximal after 30 min injection and lasted for 120 min. the effect was unaltered by pretreatment with naloxone (8.2 mu mol kg(-1), s.c.) or bilateral adrenalectomy.3 TRI (41 and 136 mu mol kg(-1), i.p.) produced a dose-related decrease of the late phase of formalin-induced nociception by 79 and 98%, respectively. At 136 mu mol kg(-1), i.p., TKI also shortened the duration of paw licking in the early phase by 69%. TKI (41 and 136 mu mol kg(-1), i.p.) also reduced the capsaicin-induced nociceptive response (by 51 to 79%).4 TKI (41 pmol kg(-1), i.p. or 410 mu mol kg(-1), s.c.) reduced the oedematogenic response, from the second to the fifth hour after carrageenin injection by 36 to 30% or by 47 to 39%, respectively.5 Pretreatment with TKI (41 mu mol kg(-1), i.p.) reduced the capsaicin-induced neurogenic inflammation in the mouse ear by 54%.6 It is concluded that TKI presents antinociceptive and antiinflammatory activities mediated by inhibition of kinin formation by tissue kallikrein in mice. the results also indicate that the tissue kallikrein-dependent pathway contributes to kinin generation in nociceptive and inflammatory processes in mice.Universidade Federal de São Paulo, Escola Paulista Med, Dept Pharmacol, Nat Prod Sect, BR-04044020 São Paulo, SP, BrazilUniversidade Federal de São Paulo, Escola Paulista Med, Dept Biophys, BR-04044020 São Paulo, SP, BrazilUniversidade Federal de São Paulo, Escola Paulista Med, Dept Pharmacol, Nat Prod Sect, BR-04044020 São Paulo, SP, BrazilUniversidade Federal de São Paulo, Escola Paulista Med, Dept Biophys, BR-04044020 São Paulo, SP, BrazilWeb of ScienceNature Publishing GroupUniversidade Federal de São Paulo (UNIFESP)Emim, José ADSouccar, Caden [UNIFESP]Castro, Maria SDGodinho, Rosely Oliveira [UNIFESP]Cezari, Maria HSJuliano, Luiz [UNIFESP]Lapa, Antonio José [UNIFESP]2016-01-24T12:31:07Z2016-01-24T12:31:07Z2000-07-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersion1099-1107http://dx.doi.org/10.1038/sj.bjp.0703362British Journal of Pharmacology. Basingstoke: Nature Publishing Group, v. 130, n. 5, p. 1099-1107, 2000.10.1038/sj.bjp.07033620007-1188http://repositorio.unifesp.br/handle/11600/26331WOS:000088067100018engBritish Journal of Pharmacologyinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UNIFESPinstname:Universidade Federal de São Paulo (UNIFESP)instacron:UNIFESP2023-05-18T14:58:13Zoai:repositorio.unifesp.br/:11600/26331Repositório InstitucionalPUBhttp://www.repositorio.unifesp.br/oai/requestbiblioteca.csp@unifesp.bropendoar:34652023-05-18T14:58:13Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)false
dc.title.none.fl_str_mv Evidence for activation of the tissue kallikrein-kinin system in nociceptive transmission and inflammatory responses of mice using a specific enzyme inhibitor
title Evidence for activation of the tissue kallikrein-kinin system in nociceptive transmission and inflammatory responses of mice using a specific enzyme inhibitor
spellingShingle Evidence for activation of the tissue kallikrein-kinin system in nociceptive transmission and inflammatory responses of mice using a specific enzyme inhibitor
Emim, José AD
tissue kallikrein inhibitor
kinins
nociception
inflammation
title_short Evidence for activation of the tissue kallikrein-kinin system in nociceptive transmission and inflammatory responses of mice using a specific enzyme inhibitor
title_full Evidence for activation of the tissue kallikrein-kinin system in nociceptive transmission and inflammatory responses of mice using a specific enzyme inhibitor
title_fullStr Evidence for activation of the tissue kallikrein-kinin system in nociceptive transmission and inflammatory responses of mice using a specific enzyme inhibitor
title_full_unstemmed Evidence for activation of the tissue kallikrein-kinin system in nociceptive transmission and inflammatory responses of mice using a specific enzyme inhibitor
title_sort Evidence for activation of the tissue kallikrein-kinin system in nociceptive transmission and inflammatory responses of mice using a specific enzyme inhibitor
author Emim, José AD
author_facet Emim, José AD
Souccar, Caden [UNIFESP]
Castro, Maria SD
Godinho, Rosely Oliveira [UNIFESP]
Cezari, Maria HS
Juliano, Luiz [UNIFESP]
Lapa, Antonio José [UNIFESP]
author_role author
author2 Souccar, Caden [UNIFESP]
Castro, Maria SD
Godinho, Rosely Oliveira [UNIFESP]
Cezari, Maria HS
Juliano, Luiz [UNIFESP]
Lapa, Antonio José [UNIFESP]
author2_role author
author
author
author
author
author
dc.contributor.none.fl_str_mv Universidade Federal de São Paulo (UNIFESP)
dc.contributor.author.fl_str_mv Emim, José AD
Souccar, Caden [UNIFESP]
Castro, Maria SD
Godinho, Rosely Oliveira [UNIFESP]
Cezari, Maria HS
Juliano, Luiz [UNIFESP]
Lapa, Antonio José [UNIFESP]
dc.subject.por.fl_str_mv tissue kallikrein inhibitor
kinins
nociception
inflammation
topic tissue kallikrein inhibitor
kinins
nociception
inflammation
description 1 the pharmacological activity of phenylacetyl-Phe-Ser-Arg-N-(2,4-dinitrophenyl)-ethylenediamine (TKI), a tissue kallikrein specific inhibitor, was assessed using models of nociception and inflammation in mice.2 Injection of TKI (13.6-136 mu mol kg(-1), i.p. or 41-410 mu mol kg(-1), s.c.) produced a dose-related inhibition of the acetic acid-induced writhes (by 37 to 85% or 34 to 80%, respectively). the antinociceptive activity of TKI (41 mu mol kg(-1), i.p.) was maximal after 30 min injection and lasted for 120 min. the effect was unaltered by pretreatment with naloxone (8.2 mu mol kg(-1), s.c.) or bilateral adrenalectomy.3 TRI (41 and 136 mu mol kg(-1), i.p.) produced a dose-related decrease of the late phase of formalin-induced nociception by 79 and 98%, respectively. At 136 mu mol kg(-1), i.p., TKI also shortened the duration of paw licking in the early phase by 69%. TKI (41 and 136 mu mol kg(-1), i.p.) also reduced the capsaicin-induced nociceptive response (by 51 to 79%).4 TKI (41 pmol kg(-1), i.p. or 410 mu mol kg(-1), s.c.) reduced the oedematogenic response, from the second to the fifth hour after carrageenin injection by 36 to 30% or by 47 to 39%, respectively.5 Pretreatment with TKI (41 mu mol kg(-1), i.p.) reduced the capsaicin-induced neurogenic inflammation in the mouse ear by 54%.6 It is concluded that TKI presents antinociceptive and antiinflammatory activities mediated by inhibition of kinin formation by tissue kallikrein in mice. the results also indicate that the tissue kallikrein-dependent pathway contributes to kinin generation in nociceptive and inflammatory processes in mice.
publishDate 2000
dc.date.none.fl_str_mv 2000-07-01
2016-01-24T12:31:07Z
2016-01-24T12:31:07Z
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://dx.doi.org/10.1038/sj.bjp.0703362
British Journal of Pharmacology. Basingstoke: Nature Publishing Group, v. 130, n. 5, p. 1099-1107, 2000.
10.1038/sj.bjp.0703362
0007-1188
http://repositorio.unifesp.br/handle/11600/26331
WOS:000088067100018
url http://dx.doi.org/10.1038/sj.bjp.0703362
http://repositorio.unifesp.br/handle/11600/26331
identifier_str_mv British Journal of Pharmacology. Basingstoke: Nature Publishing Group, v. 130, n. 5, p. 1099-1107, 2000.
10.1038/sj.bjp.0703362
0007-1188
WOS:000088067100018
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv British Journal of Pharmacology
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 1099-1107
dc.publisher.none.fl_str_mv Nature Publishing Group
publisher.none.fl_str_mv Nature Publishing Group
dc.source.none.fl_str_mv reponame:Repositório Institucional da UNIFESP
instname:Universidade Federal de São Paulo (UNIFESP)
instacron:UNIFESP
instname_str Universidade Federal de São Paulo (UNIFESP)
instacron_str UNIFESP
institution UNIFESP
reponame_str Repositório Institucional da UNIFESP
collection Repositório Institucional da UNIFESP
repository.name.fl_str_mv Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)
repository.mail.fl_str_mv biblioteca.csp@unifesp.br
_version_ 1814268349736026112